{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '1', 'FLOW CHARTS', '1.1', 'GRAPHICAL STUDY DESIGN', 'Maintenance', 'Titration Phase', 'Phase', 'Screening period', '(3 weeks)', '(1 week)', 'Follow up', '(up to 6 weeks**)', '(1 week)', 'Additional 1 week', 'on tolerated dose', 'N= 39', 'End of', 'patients', 'Study', '2 days', 'N= 39', 'patients', 'Weeks:', '-6', '0', '1', '2', '3', '4', '5', 'Visits at:', 'Screening', 'D1', 'D8', 'D15', 'D22', 'D29', 'D36', '*', 'See titration rules in next pages,', '** For patients with stable angina due to MVA without PCI, who need CCTA during screening period, additional', 'R: randomization', 'On-site visits', '2 weeks of screening are allowed thus having a maximal screening period of up to 6 weeks.', 'Property of the Sanofi Group - strictly confidential', 'Page 9', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '1.2', 'POTENTIAL TITRATION SCHEDULES & DECISION RULES STUDY', '1.', '2.', '3.', '4.', '5.', '6.', '7.', '8.', 'In case a patient does not tolerate a dose, he/she call the investigator to have an on-site visit. Based on the tolerability assessed at this visit, the investigator could decide to stop or modify study drug dose.', 'Dose titration based on BP tolerability at visits as per Section 9.2.4.3 with the following recommendations:', 'Stopping criterion based on creatinine level:', 'Stop study drug if creatinine blood level >150 mol/L and increase from baseline >30%. In specific circumstances where creatinine blood level can be obtained only in the afternoon the day of the visit, the', 'patient will be titrated according to titration scheme and if creatinine blood level meets stopping rules, the investigator will need to contact the patient before bedtime study drug intake as study drug should', 'be permanently discontinued and a premature study drug discontinuation visit will be planned as per Section 8.1.1.', 'Property of the Sanofi Group - strictly confidential', 'Page 10', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '1.3', 'STUDY FLOW CHARTS', '1.3.1 Study flow chart for patients with previous coronary artery angiography or CCTA within 24 months prior to screening', 'Maintenance', 'Phase', 'Screening', 'Titration Phase', 'Phase', 'End-of-study', 'D-28 to D-1', 'D1', 'D8', 'D15', 'D22', 'D29', 'D36', '(see separate', '(+/-2days)', '(+/-2days)', '(+/-2days)', '(+2days)', '(+/-2days)', 'flow chart for this', 'EOT/early', 'visit)', 'discontinuation', 'Informed consent', 'X', 'Visit at clinical site', 'X', 'Xa', 'X', 'X', 'X', 'xa', 'X', 'Data of previous coronary artery angiography', 'or CCTA', 'xb', 'Inclusion/exclusion criteria', 'X', 'X', 'Medical/surgical history', 'X', 'Prior/concomitant medications', '<---', '----', 'IVRS/IWRS', 'X\u00b0', 'XP', 'XP', 'XP', 'XP', 'X', 'Randomization', 'X', 'IMP administrationd', '<---', 'IMP dispensation', 'X', 'X', 'X', 'Xq', 'Safety', 'Physical examination', 'X', 'X', 'X', 'Height', 'X', 'Body weight', 'X', 'X', 'X', 'Vital signse (including search for orthostatic', 'X', 'xf,g', 'xf', 'xf', 'xf', 'xf,g', 'X', 'BP), ECGs', 'Body temperature', 'X', 'X', 'Hematology, biochemistry, urinalysis', 'X', 'X', 'XS', 'xns', 'xns', 'X', 'XS', 'Renal function (blood creatinine and cystatin', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'C)', 'Plasma FSHM', 'X', 'Adverse event collection', '<---', '----', '----', 'Pharmacodynamics', 'Data of previous CFR assessment whatever', 'xb', 'the method', 'CFR assessed by vasodilator stress PET', 'xi', 'xi', 'Property of the Sanofi Group - strictly confidential', 'Page 11', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}